Compare NFE & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NFE | TRDA |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 386.8M |
| IPO Year | 2019 | 2021 |
| Metric | NFE | TRDA |
|---|---|---|
| Price | $1.17 | $10.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $7.70 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 9.0M | 185.3K |
| Earning Date | 02-27-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,768,624,000.00 | $61,520,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.93 | $3.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.98 | $4.93 |
| 52 Week High | $16.66 | $17.15 |
| Indicator | NFE | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 47.31 | 53.65 |
| Support Level | $1.04 | $9.87 |
| Resistance Level | $1.30 | $10.88 |
| Average True Range (ATR) | 0.09 | 0.51 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 57.69 | 44.68 |
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.